A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report
Authors Huang Y, Xu J, Li K, Wang J, Dai Y, Kang Y
Received 12 August 2020
Accepted for publication 11 March 2021
Published 29 March 2021 Volume 2021:13 Pages 2849—2867
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Alexandra R. Fernandes
Yunke Huang,* Jing Xu,* Ke Li, Jing Wang, Yilin Dai, Yu Kang
The Obstetrics & Gynecology Hospital of Fudan University, Gynecology Department, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yu Kang
The Obstetrics & Gynecology Hospital of Fudan University, Gynecology Department, No. 419, Fangxie Road, Huangpu District, Shanghai, People’s Republic of China
Tel +86 136 36328211
Email [email protected]
Purpose: With this study, we intended to construct a personalized drug-screening system for platinum-resistant ovarian cancer patients by consulting a patient’s medical history, data derived from gene mutation detection, and drug screening results derived from mini-PDX (patient-derived xenograft) models. We also aimed to evaluate the efficacy and safety of our system.
Patients and Methods: We selected 12 patients with platinum-resistant ovarian cancer who were treated at our hospital from January 2018 to December 2019 to design a single-arm clinical trial. The subsequent chemotherapeutic plans were selected according to a personalized drug-screening system that circulating tumor DNA (ctDNA) testing and the establishment of mini-PDX models. We then analyzed the patients for clinical benefits side-effects in response to chemotherapy in order to evaluate the clinical effects and safety of our new personalized drug-selection system.
Results: We successfully established an individualized and sensitive drug-screening system for the 12 patients. Mini-PDX models verified that potentially effective drugs were identified for 11 of the patients. Treatment resulted in complete remission (one patient), partial remission (five patients), and stable disease (three patients). The remaining three patients experienced disease progression. The overall clinical-benefit rate was 75.0%. Following treatment, the levels of CA125 levels decreased significantly in seven of the 12 patients. Severe side effects, arising from chemotherapy, were only observed in one case.
Conclusion: Constructing a personalized drug-screening system for platinum-resistant ovarian cancer patients can be used to guide clinical drug selection and improve the clinical-benefit rate for patients.
Trial Registration Number: ChiCTR1800016766 (Chinese Clinical Trial Registry Center).
Keywords: drug resistance, ovarian cancer, precision medicine, personalized drug-screening system
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]